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Total RNA was isolated from explants using RNeasy@ Plus Universal Mini Kit (QIAGEN, Toronto, ON, 83! Canada) according to the manufacturer's instructions. RNA concentration and purity were assessed using 84! the NanoDrop 1000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and Experion RNA 85! StdSens Analysis Kit (Bio Rad, Mississauga, ON, Canada), respectively. RNA was reverse-transcribed to 86! cDNA using the iScript Reverse Transcription Supermix (Bio Rad, Canada) . mRNA levels of the ABCB1 87! (P-gp), ABCG2 (BCRP), TLR-3, TLR-4, interleukin (IL)-8 (a pro-inflammatory cytokine) and chemokine 88! (C-C motif) ligand 2 (CCl2 ) was measured by qPCR using SYBR Green reagent (Sigma-Aldrich, USA) 89! and the CFX 380 Real-Time system C 1000 TM Thermal Cycle (Bio Rad, Canada) , with the following 90! cycling conditions: initial enzyme 95 o C for 5 min followed by 38 cycles of 95 o C for 15s and 60 o C for 91! 20s. Gene specific primers are shown in Table I 24, 25 . Gene expression was normalized to the geometric 92! mean of the following selected reference genes (table I) which showed stable expression levels after LPS 93! and Poly I:C treatments in first and third trimester tissues: the zeta polypeptide (YWHAZ) and succinate-94! ubiquinone oxidoreductase (SDHA) genes in the first trimester; YWHAZ and DNA topoisomerase 1 95! (TOP1) in the third trimester. Levels of placental TLR-3 and TLR-4 mRNA from first and third trimester 96! explants were normalized to the geometric mean of YWHAZ and cytochromec-1 (CYC1), which showed 97! stable expression levels in the first and third trimester tissues. Viability of the explants subjected to treatment with LPS (0.1, 1, 10 ug/ml) or Poly I:C (1, 10, 50 ug/ml) 116! was determined by measuring lactate dehydrogenase (LDH) leakage into the medium as previously 117! described 4, 11 . Briefly, LDH was quantified using the Cytotoxicity Detection kit (Roche Applied Science, 118! Indianapolis, USA) according to the manufacturer's instructions. A standard curve for the LDH assay was 119! generated using L-lactic dehydrogenase from rabbit muscle (Sigma) whereas absorbance was measured at 120! 490 nm (Biotek, Winooski, VT, USA 
Statistical analysis 146!
Exploratory data analyses were performed using Prism (GraphPad Software Inc, San Diego, CA). 147! Differences in mRNA levels between first and third trimester were assessed using un-paired t-tests.
148!
Differences in mRNA levels in explants exposed to LPS and Poly I:C were assessed using two-way 149! ! ! 8! ANOVA followed by Bonferonni's test. Differences in cytokine and protein levels were assessed using 150! a paired t-test. Differences were considered statistically significant when p< 0.05.
151! 152!

Results
153!
TLR-3 and TLR-4 expression and localization in the first and third trimester placenta.
154!
Both first and third trimester placental explants expressed TLR3 and TLR4 mRNA. Levels of both 155! receptors were higher in the third trimester compared to the first trimester (p<0.05 and p<0.01, 156! respectively) (Fig. 1A-B) . Accordingly, TLR-3 and TLR-4 immunostaining intensity was increased in 157! third trimester explants. In the first trimester, TLR-3 and TLR-4 protein was localized to the 158! cytotrophoblast, whereas in the third trimester both were localized to the syncytiotrophoblast.
159!
Additionally, third trimester explants also exhibited TLR-3 immunostaining in cells of the villous core. 160! (Fig. 1C) .
161! 162!
Effect of LPS on expression of P-gp/ABCB1 and BCRP/ABCG2 mRNA and protein expression 163!
In order to simulate the effects of bacterial infection on P-gp and BCRP expression, villous explants were 164! treated with three doses of LPS (0.1, 1, 10 ug/mL) for 4h and 24h. There was a gestational age-dependent 165! effect of LPS on ABCB1/P-gp and ABCG2/BCRP mRNA and protein levels. While there was a 166! significant decrease in ABCB1 (p<0.01) and ABCG2 mRNA (p<0.001) levels at 24h after LPS treatment 167! in the first trimester explants ( Fig. 2A, C) , there was no effect on ABCB1 and ABCG2 mRNA levels in 168! third trimester explants (Fig. 2B, D) . Similarly, LPS decreased P-gp and BCRP protein levels (p<0.05) 169! after 24h in first trimester explants (Fig. 2G, I ), but did not alter P-gp and BCRP protein levels in the third 170! trimester explants (Fig. 2H, J) . In order to simulate the effects of viral infection on P-gp and BCRP expression, villous explants were 174! treated with three doses of Poly I:C (1, 10, 50 ug/mL) for 4h and 24h. Poly I:C did not alter P-gp/ABCB1 175! ! ! 9! or BCRP/ABCG2 mRNA or protein levels in the first trimester explants (Fig. 3A, C, G, I ). In third 176! trimester explants, Poly I:C induced a dose-dependent decrease in ABCB1 mRNA levels after 24h 177! (p<0.05) (Fig. 3B) . However, Poly I:C had no effect on ABCG2 mRNA levels or the protein levels of 178! either transporter (Fig. 3D, H, J) . 179!
180!
Effect of LPS and Poly I:C on TLR-3 and TLR-4 mRNA expression 181! Two-way ANOVA analysis revealed a significant increase in TLR-3 and TLR-4 mRNA levels over the 24 182! h culture period in the first trimester explants. However, LPS treatment did not alter TLR-3 or TLR-4 183! mRNA levels in either the first or third trimester tissues (Fig.4 A-D) . Poly I:C had no effect on TLR-3 or 184! TLR-4 expression in the first trimester explants, but induced a dose-dependent decrease (p<0.001) of 185! TLR-3 and TLR-4 mRNA levels in the third trimester explants (Fig. 4E-H) .
186! 187!
Placental inflammatory response to LPS and Poly I:C .
188!
To confirm that the explants were responsive to LPS and Poly I:C the expression of the pro-inflammatory 189! markers IL-8 and the chemokine CCl2 was evaluated. In the first trimester, LPS increased IL-8 mRNA 190! (p<0.01) and CCl2 mRNA levels (p<0.05) after 4h and 24h (p<0.05) (Fig. 5A, C) . In the third trimester, 191! LPS increased IL-8 mRNA levels after 4h (p<0.05) and 24 h (p<0.01). CCL2 mRNA levels were 192! increased (p<0.05) after 4h of LPS exposure but returned to baseline after 24h (Fig. 5B, D) .
193! 194!
Poly I:C, induced significant increases in IL-8 (p<0.01) and CCL2 mRNA (p<0.01) levels after 24h in 195! first trimester tissues (Fig. 5E, G) . In third trimester tissues, Poly I:C increased IL-8 mRNA levels at 4h 196! (p<0.05) and 24h (p<0.01) and CCL2 mRNA levels were increased after 4h (p<0.05) and showed a strong 197! trend towards increased CCL2 mRNA levels after 24 h (Fig. 5F, H) .
198! 199!
Villous structural integrity and viability of first and third trimester explants. 200! ! ! 10! Placental explants prior to culture, after 24h of culture (equivalent to time 0 for LPS and Poly I:C 201! treatment) and after 48h of culture (equivalent to 24h treatment) were examined to confirm the structural 202! integrity of the explants (Fig. 6A) . NTRK2, the receptor for brain derived neurotrophic factor (BNDF), 203! which is constitutively expressed in cytotrophoblast and syncytiotrophoblast in the human placenta 26, 27 204! was clearly localized to those structures in the explants (Fig. 6B ). In addition, there was no effect of LPS 205! or Poly I:C on the release of LDH into the culture media in either first or third trimester explants (data 206! not shown), demonstrating that explants were viable after culture and treatments. 
227!
Acute sub-lethal LPS exposure decreased P-gp activity in the mouse placenta 12 , promoting increased P-228! gp substrate accumulation in the fetus. In the rat, LPS down-regulated placental Abcb1a/b and Abcg2 229! mRNA 15, 28 . Other studies found that LPS treatment to decreased levels of P-gp/Abcb1a mRNA and 230! protein in rat liver, brain and heart 15, 29 . Together, these data suggest that infection/inflammation is 231! capable of inducing changes in the levels of drug transporters, particularly P-gp and BCRP. This alters the 232! biodistribution of xenobiotics in a variety of tissues and across biological barriers, including the placenta.
233!
This would result in increased fetal accumulation of toxins and xenobiotics that may be present at the 234! maternal circulation. Our data also suggest that, at least with respect to drug transporters, the placenta 235! exhibits a differential response to infectious agents and this effect is greater for bacterial challenge 236! compared to that of viral challenge. Moreover, the first trimester placenta appears to be more sensitive to 237! the effects of bacterial infection, potentially leading to increased exposure of the embryo/fetus to drugs 238! and toxins at a critical time in development and that bacterial infection may have a greater impact on 239! transporter expression in the first trimester. 240!
241!
Previous studies have demonstrated that Poly I:C decreases the expression of placental Abcb1a/b and 242! Abcg2 mRNA in the rat 16 . In contrast, Poly I:C induced the expression of Abcb1b mRNA, but down-243! regulated P-gp and BCRP protein levels in rat liver 16 . In the present study, the impact of viral and 244! bacterial infection appears to be different depending on gestational age. In the first trimester, explants 245! were responsive to bacterial but not viral challenge. However, in the third trimester, expression of drug 246! transporters is reduced by viral, but not bacterial challenge. It is possible that a longer duration of 247! exposure is required for an effect on drug transporter in third trimester explants. While 24 hours exposure 248! to infectious agents was sufficient to generate a response in the first trimester, this might not be the case 249! for third trimester explants, though we did demonstrate that first and third trimester explants mounted a 250! similar inflammatory response (cytokines and chemokines) after LPS/Poly I:C exposure. Further studies 251! are required to determine the time-dependency of these effects. 252! ! ! 12! Developmental expression and localization of TLR-3 and TLR-4 may also play a role in determining 253! the pattern of expression of drug transporters in response to bacterial and viral challenge. We 254! demonstrated that TLR-4 is more abundantly expressed in the third trimester than the first trimester 255! placenta; consistent with previous findings demonstrating that TLR-4 expression is increased at term 256! compared to earlier stages of pregnancy 17 . Additionally, we have shown, for the first time, that there is a 257! gestational-age dependent pattern of expression for TLR-3, with increasing TLR-3 levels in the third 258! trimester placenta. This is somewhat counterintuitive given that first trimester placentas challenged with 259! LPS showed decreased P-gp/ABCB1 and BCRP/ABCG2 expression whereas third trimester placentas did 260! not. These differences might be explained by the gestational age-dependent pattern of TLR-4 localization 261! in the placenta. TLR-4 was localized to cytotrophoblast in the first trimester and in the 262! syncytiotrophoblast layer in the third trimester placenta as described previously 17 . It may be that TLR-4 263! localized to the cytotrophoblast cells, when activated by TLR-4 ligands is capable of inducing changes in 264! multidrug transporters in the first trimester placenta, whereas, activation of TLR-4 in the third trimester 265! syncytiotrophoblast is not. 266!
267!
Other than playing an important role in transporting xenobiotics, the ABC transporters also efflux a wide 268! variety of substrates across cellular membranes including: metabolic products (amino acids), lipids 269! (cholesterol), steroid hormones (i.e. betamethasone), environmental toxins (i.e. ivermectin and bisphenol-270! A), compounds involved in inflammatory response and regulators of leukocyte invasion in non-uterine 271! tissues 3, 30 . Importantly, blocking activity of P-gp in astrocytes, reduced CCL2 secretion 31 , an important 272! uterine chemokine 32 . Moreover, P-gp has been shown to actively transport pro-inflammatory cytokines 273! out of cells 31, 33 . As such, P-gp likely plays an important role in the secretion of pro-274! inflammatory/chemotactic factors into the extracellular space and therefore in the regulation of 275! immunological responses. In addition, the trophoblast can secrete a wide variety of cytokines/chemokines 276! that are involved with immune chemotaxis 21, 22, 34, 35 playing an important role in mediating local 277! immunological responses to protect the fetus from viral or bacterial infections. Therefore, it is tempting to 278! ! ! 13! speculate that modulation of multidrug transporters expression in response to bacterial/viral infection 279! may also be part of the trophoblast-specific immunological responses to infection, which seems to be 280! gestational age-and infective agent-dependent.
281! 282!
It is also important to stress that TLRs are essential components of the signaling network within the 283! innate immune response, which increase cytokine release to protect the fetus against preterm delivery in 284! the context of infection 36, 37 . Our results indicate that LPS and Poly I:C can elicit a robust cytokine and 285! chemokine response (IL-8, CCL2) in both first and third trimester placental explants. Thus, the lack of 286! effect of LPS or Poly I:C on drug transporters in the third trimester is not due to a hypo-responsiveness to 287! infection. Our results corroborate those of previous studies, demonstrating that the responsiveness of drug 288! transporters to TLRs ligands in trophoblast is highly gestational age-dependant 12 . We also demonstrated 289! that LPS and Poly I:C treatment did not alter explant viability (as determined by LDH measurements) or 290! structure, demonstrating that decreases in P-gp/ABCB1 and BCRP/ABCG2 expression are not likely 291! caused by impaired explant viability. 292!
293!
In conclusion, our data show that bacterial and viral challenge can reduce the expression of the multi-drug 294! transporters in the human placenta. The modulation of these drugs transporters is gestational-age 295! dependent, with the placenta being more sensitive to bacterial challenge during the first trimester and 296! viral challenge in the third trimester. This does not appear to be due to a lack of response of recognition 297! of these agents through TLRs, since activation of both TLR-3 and TLR-4 elicit robust cytokine responses 298! in both the first and third trimesters. Since intrauterine infection/inflammation is relatively common 299! during pregnancy (and associated with significant pregnancy pathologies), the consequent reduction in the 300! expression of drug transporters may expose the embryo/fetus to potentially harmful agents drugs, toxins 301! and hormones crossing from the maternal circulation at a time when it is most vulnerable. 
